Viva San Diego!

Not all inhibitors – even in the same class – are equal.

As the flood of KRAS directed agents into the clinic continues, so too does scrutiny on the selection criteria and baseline characteristics.

After all, a less heavily pretreated population can influence the activity and safety profiles reported.

Inreasingly we are seeing more data emerge looking at the resistance mechanisms occuring in reponse to various therapies. There are a number of important emerging questions begining to arise.

For example, if we only target the OFF or ON states, will this leave more opportunities for early escape on the other side?  What if we target both OFF and ON states as well as wild-type KRAS – will this lead to delayed resistance and improved outcomes for patients with KRAS mutated cancers?

It was only just a couple of years ago when G12C inhibitors were all the rage and few observers paid any real attention to drugging additional mutations beyond the initial target.

In the latest report on this niche we’re mostly going to focus on a couple of different mutations not named G12C – including an expert interview with a promising up and coming biotech – as we continue to segue our coverage between AACR and ASCO…

To learn more from our latest oncology expert interview and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by